U.S. Telecom Services and Carriers Stock News

In early June 2026, Schafer Cullen Capital Management highlighted Belden’s ongoing shift toward higher-growth, higher-margin businesses, driven by divestitures and reinvestment into areas such as industrial automation and data infrastructure. This portfolio reshaping aims to improve profitability and strengthen Belden’s role in reliable connectivity, while existing risks like elevated debt levels and slower expected revenue expansion remain present. Next, we’ll examine how Belden’s...

Bruker (BRKR) stock is in focus after the company used ASM Microbe 2026 to spotlight new FDA-backed capabilities for its MALDI Biotyper CA System, alongside broader launches in diagnostics and ultra-high-resolution mass spectrometry. See our latest analysis for Bruker. Recent news around new diagnostics capabilities and conference appearances comes as Bruker’s share price has pulled back 6% in the last day and 4% over the week, after a strong 52% 3 month share price return and 48% 1 year...

Pool stock performance snapshot Without a clear headline event, Pool (POOL) is drawing attention as investors reassess its recent share performance and fundamentals. The stock last closed at US$185.52, with a market value of about US$6.8b. See our latest analysis for Pool. The 1 day share price return of 1.26% and 7 day gain of 2.27% sit against a weaker backdrop, with the 90 day share price return down 13.52% and the 1 year total shareholder return down 36.16%, which indicates that recent...

Four Corners Property Trust recently acquired 14 Sun Auto Tire & Service properties for US$26.0 million across Missouri, Arkansas, and Illinois, all under long-term triple net leases priced at a cap rate consistent with its prior deals. In a separate move, FCPT agreed to buy up to 102 Mission Pet Health veterinary properties for up to US$268.0 million, which would materially increase its medical retail exposure and reduce reliance on legacy restaurant tenants once closed. Now we’ll consider...

Cleveland-Cliffs (CLF) has been in focus after a sharp move in its stock, tied to sector optimism in steel, lower tariffs on certain steel imports, and fresh recognition from a key automotive customer. See our latest analysis for Cleveland-Cliffs. The recent pullback, with a 1-day share price return of 6.24% and the stock now at US$13.53, comes after a strong 30-day share price return of 22.78% and a 90-day gain of 41.68%. The 1-year total shareholder return of 78.03% contrasts with weaker 3...

Why Herc Holdings Stock Is On Investors’ Radar Herc Holdings (HRI) has drawn fresh attention after recent trading left the stock around $136.68, with returns mixed across short and longer periods, prompting investors to reassess the equipment rental specialist. See our latest analysis for Herc Holdings. The recent pullback to a share price of $136.68 comes after a 1-day share price return that declined 2.69%, although the 90-day share price return of 12.81% and 1-year total shareholder return...

Everest Group has recently filed an 8-K and recast its 2025 10-K after selling renewal rights for its Commercial Retail Insurance business, reorganizing into Reinsurance Treaty, Global Wholesale & Specialty, and Legacy segments to reflect its updated operating focus. This restructuring clarifies how Everest Group now allocates capital and reports performance around core reinsurance and wholesale specialty activities, giving investors a cleaner view of each segment’s role and risk...

Recent performance snapshot and why Enphase Energy (ENPH) is on investor radar Enphase Energy (ENPH) has drawn fresh attention after a sharp pullback of about 18% over the past week, even as the stock is still up strongly year to date and over the past month. See our latest analysis for Enphase Energy. The recent 1 day share price decline of about 18% to US$56.07 comes after a sharp 30 day share price return of 53.83% and a year to date share price return of 66.13%. The 1 year total...

How Silgan Holdings (SLGN) Stock Has Been Performing Silgan Holdings (SLGN) has drawn investor attention after a weak stretch for the stock, with the share price down about 9% over the past month and 17% over the past 3 months. Over the past year, the stock has declined about 31%, while the return since the start of the year is down roughly 11%. In that context, some investors are revisiting the company’s valuation and fundamentals. See our latest analysis for Silgan Holdings. At a share...

Capital markets deal puts spotlight on Marcus & Millichap stock Marcus & Millichap (MMI) is back on investor radars after its IPA Capital Markets division arranged $123 million in debt financing, plus preferred equity, for a 268 unit luxury multifamily property in Burlingame, California. See our latest analysis for Marcus & Millichap. The financing headline lands at a time when momentum in the stock has been mixed, with a 7 day share price return of 6.59% and a 90 day share price return of...

California Resources Corporation recently achieved the first carbon dioxide injection at its Carbon TerraVault I project at Elk Hills Field in Kern County, marking California’s first operational carbon capture and storage facility capable of ultimately storing up to 38 million metric tons of CO2 in depleted oil and gas reservoirs. This initial injection not only reduces CRC’s own operational emissions but also creates a new market for industrial CO2 storage in the state, potentially...

Highwoods Properties (HIW) recently recast a $150 million unsecured bank term loan, extending the maturity to June 2031 with options for further extensions, and linking pricing to both SOFR and greenhouse gas reduction targets. See our latest analysis for Highwoods Properties. The refinancing news has arrived alongside stronger price momentum, with a 7 day share price return of 6.82% and a 90 day share price return of 26.96%, while the 1 year total shareholder return has declined 3.19%...

Crinetics Pharmaceuticals recently highlighted that six data presentations on its oral acromegaly drug PALSONIFY and investigational ACTH-receptor antagonist atumelnant were delivered at ENDO 2026, covering up to two years of efficacy and safety data, real-world treatment patterns, and Phase 2 results across congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The focus on long-term outcomes, real-world biochemical control, and dose selection for Phase 3 trials gives...

In its recently reported fiscal second-quarter 2026 results, Adient plc delivered an earnings beat with revenue growth supported by favorable foreign exchange and higher volumes, although profitability was pressured by customer-driven production inefficiencies and incremental launch-related spending across regions. An interesting takeaway is that these mixed operating trends coincided with Adient being highlighted by Zacks Investment Research as a strong value stock within the automotive...

In recent days, Wayfair faced renewed scrutiny as investors weighed rising interest rates, insider share sales worth US$37.5 million over three months, and concerns about profitability and valuation against ongoing operational upgrades and promotional efforts such as its post-holiday Warehouse Sale. At the same time, Wayfair has been rolling out logistics and delivery enhancements, including automation and more precise delivery options, which aim to improve customer experience and reduce...

Earlier this week, analysts upgraded Ameris Bancorp to an A+ EPS Revision Grade, citing stronger earnings momentum and a more favorable earnings outlook for the bank. An interesting angle is that this upgrade comes alongside steady insider activity, with no recent buying or selling, pointing to management’s apparent comfort with current performance trends. Next, we’ll consider how this stronger earnings momentum, reflected in the A+ EPS Revision Grade, may influence Ameris Bancorp’s existing...

Immunome, Inc. recently reported detailed efficacy and safety data from its global Phase 3 RINGSIDE trial of varegacestat in progressing desmoid tumors, showing statistically significant improvements in progression-free survival and pain, and confirming that a New Drug Application was submitted to the US FDA in April 2026 with a European filing planned. An interesting aspect for investors is that the progression-free survival benefit appeared consistent across prespecified patient subgroups,...

Independence Realty Trust (IRT) sits in focus for income oriented investors after a mixed set of recent return figures, including a decline of 5.6% year to date and a 4.8% fall over the past year. See our latest analysis for Independence Realty Trust. The recent 7 day share price return of 2.4% to around US$16.62 contrasts with weaker year to date share price performance and only modest multi year total shareholder returns. This suggests momentum has been soft rather than accelerating. If you...

LGI Homes recently reported that it closed 498 homes in May 2026, a 19.7% year-over-year increase, and is expanding its footprint with new communities such as Trails West near Jacksonville and the Novo Collection at Hallimore Ranch in the Houston market. These openings in fast-growing Sun Belt corridors, combined with stronger monthly closings, suggest LGI Homes is actively rebuilding volume despite earlier signs of revenue pressure and balance sheet strain. We’ll now examine how this...

LoanCare’s CoreSync launch puts Fidelity National Financial (FNF) digital mortgage servicing in focus Fidelity National Financial (FNF) is in the spotlight after subsidiary LoanCare rolled out CoreSync, a private label mortgage servicing platform designed to plug directly into banks, credit unions, and IMBs' existing digital channels. See our latest analysis for Fidelity National Financial. The CoreSync announcement lands at a time when momentum in Fidelity National Financial’s stock has...

Structure Therapeutics (GPCR) moved into focus after publishing detailed Phase 2b ACCESS data for its oral GLP-1 candidate aleniglipron in Nature Medicine, alongside presentations at the American Diabetes Association’s 86th Scientific Sessions. See our latest analysis for Structure Therapeutics. Despite the positive ACCESS data and a busy conference schedule in recent weeks, Structure Therapeutics' share price has come under pressure. The 90 day share price return is down 33.49% and the year...

Recent performance snapshot Globant (GLOB) has drawn investor attention after an extended period of weak share performance, with the stock down 4.8% over the past week, 2.4% over the past month, and 24.1% over the past 3 months. Over longer horizons the picture is similar. The stock is down 39.3% year to date and 62% over the past year, even as the company reports annual revenue of US$2.45b and net income of US$109.26m. See our latest analysis for Globant. At the current share price of...

Short term pullback against strong longer term gains WisdomTree (WT) has seen its stock fall 4.2% over the past day and 4.6% over the past week, extending a 4.8% decline over the past month, even as longer term returns remain strong. Over the past 3 months, WisdomTree is up 9.6%, with year to date and 1 year total returns of 45.3% and 84.9% respectively. The company currently has a market cap of about US$2.7b and last closed at US$18.18. See our latest analysis for WisdomTree. The recent drop...

Recently, Itau BBA upgraded Ternium S.A. to Outperform and Goldman Sachs reaffirmed a positive view, citing confidence in its steel industry positioning and integrated operating model. This growing analyst support contrasts with some valuation models flagging the shares as significantly overvalued and the absence of recent insider trading activity. Next, we’ll examine how this fresh analyst confidence, particularly around Ternium’s integrated model, may influence the company’s existing...